English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18054/20253 (89%)
Visitors : 24231454      Online Users : 480
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34607


    標題: The Association of Erythropoietin and Age-Related Macular Degeneration in Hemodialysis Patients: A Nationwide Population-Based Cohort Study
    作者: Huang, Evelyn-Jou-Chen
    Sung, Fung-Chang
    Hung, Peir-Haur
    Muo, Chih-Hsin
    Wu, Meei-Maan
    Yeh, Chih-Ching
    貢獻者: Taipei Medical University
    Taipei Medical University Hospital
    Taipei Medical University
    China Medical University Taiwan
    China Medical University Taiwan
    China Medical University Hospital - Taiwan
    Asia University Taiwan
    Department of Applied Life Science and Health, Chia Nan University of Pharmacy & Science
    China Medical University Taiwan
    Taipei Medical University
    Taipei Medical University
    Taipei Medical University
    China Medical University Taiwan
    Taipei Medical University
    Taipei Municipal WanFang Hospital
    關鍵字: chronic kidney-disease
    stage renal-disease
    risk-factors
    eye disease
    protects
    retina
    anemia
    cells
    serum
    日期: 2022
    上傳時間: 2023-12-11 14:00:29 (UTC+8)
    出版者: MDPI
    摘要: This population-based retrospective cohort study investigated the effectiveness of erythropoietin (EPO) treatment in reducing the risk of age-related macular degeneration (AMD) in hemodialysis patients, using the National Health Insurance Research Data of Taiwan. From the database, we identified 147,318 end-stage renal disease (ESRD) patients on hemodialysis who had been diagnosed in 2000-2014 to establish the propensity-score-matched EPO user cohort and non-EPO user cohort with equal sample size of 15,992. By the end of 2016, the cumulative incidence of AMD in EPO users was about 3.29% lower than that in non-EPO users (Kaplan-Meier survival p < 0.0001). The risk of AMD was 43% lower in EPO users than in non-EPO users, with an adjusted hazard ratio (aHR) of 0.57 (95% confidence interval (CI) = 0.51-0.64) estimated in the multivariate Cox model. A significant negative dose-response relationship was identified between the EPO dosage and the risk of AMD (p < 0.0001). Another beneficial effect of EPO treatment was a reduced risk of both exudative AMD (aHR = 0.48, 95% CI = 0.40-0.61) and non-exudative AMD (aHR = 0.61, 95% CI = 0.53-0.69), also in similar dose-response relationships (p < 0.0001). Our findings suggest that EPO treatment for hemodialysis patients could reduce AMD risk in a dose-response relationship.
    關聯: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v.23, n.17, 9634
    Appears in Collections:[生活保健科技系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    ijms23179634.pdf601KbAdobe PDF59View/Open
    index.html0KbHTML90View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback